Ultra Market Research | United States GLP-1 Market
United States GLP-1 Market
Report ID : 788
Category : Pharmaceuticals,United-States(US)
No Of Pages : 165
Published on: October 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United States GLP-1 Market Introduction The GLP-1 market in the USA focuses on medications that activate the GLP-1 receptor, aiding in the management of diabetes and obesity by enhancing insulin secretion and promoting weight loss. GLP-1 agonists, a type of incretin-based therapy, are particularly valued for their efficacy in blood glucose regulation and weight management, making them instrumental in both diabetes and obesity treatments in the United States. With a rising prevalence of diabetes and obesity, GLP-1 drugs are seeing increased demand, and the market size in the USA has been growing significantly over recent years. Recent trends in the GLP-1 market in the USA emphasize innovative, extended-release formulations and the combination of GLP-1 agonists with other therapeutic agents, further diversifying the treatment options available. Currently, the market is experiencing robust growth, driven by enhanced awareness and improved healthcare policies supporting obesity and diabetes management.
Drivers 1. Increasing prevalence of diabetes and obesity in the USA is driving demand for GLP-1 agonists to address these health issues effectively. 2. Growing awareness among healthcare professionals and patients regarding GLP-1 drugs for obesity and diabetes management is boosting market adoption. 3. Innovations in drug formulations, such as extended-release GLP-1 medications, enhance patient compliance by reducing the frequency of administration. 4. The USA’s supportive regulatory environment, including FDA approvals for novel GLP-1 therapies, accelerates product availability. 5. Positive outcomes in reducing cardiovascular risks among GLP-1 drug users attract more patients, expanding the market. 6. Healthcare policies encouraging effective chronic disease management through accessible medication options contribute to market growth.
Restraints 1. High costs associated with GLP-1 drugs may limit accessibility, particularly for uninsured or underinsured patients. 2. Side effects, including gastrointestinal discomfort, can lead to patient discontinuation, affecting the market growth. 3. Competition from alternative diabetes and obesity treatments, such as SGLT-2 inhibitors and non-drug therapies, poses a challenge. 4. Complex drug manufacturing processes for GLP-1 agonists can lead to supply chain issues, impacting availability. 5. Reimbursement challenges with insurers for obesity treatments in some cases can restrict market expansion. 6. Limited awareness among certain patient populations regarding the benefits of GLP-1 therapies may impact market penetration.
Opportunity 1. Expanding awareness campaigns by healthcare organizations about obesity and diabetes treatments increase the GLP-1 drug demand. 2. Continuous advancements in drug delivery technologies, like transdermal patches and oral formulations, enhance patient comfort. 3 Rising investment in research targeting the dual benefits of GLP-1 agonists for diabetes and cardiovascular health offers new avenues. 4. Partnerships with telemedicine services increase accessibility of GLP-1 drugs to patients across remote areas. 5. Growth in personalized medicine practices allows more tailored treatment options based on genetic and lifestyle factors, expanding market scope. 6. Increasing collaborations among pharmaceutical companies for combination therapies foster innovation and market opportunities.
Trend Recent trends in the United States GLP-1 market highlight a growing emphasis on combination therapies, where GLP-1 agonists are paired with other medications like SGLT-2 inhibitors to optimize weight loss and glycemic control. The introduction of oral GLP-1 formulations has also transformed patient preferences, as these are often more convenient compared to injectable forms. Additionally, there is increasing interest in GLP-1 treatments for weight management in non-diabetic patients, driven by rising obesity rates and evolving regulatory support for treating obesity as a chronic health condition. Advances in digital health technologies also impact the GLP-1 market by supporting patient adherence and monitoring, with apps and wearables tracking weight and blood glucose. Such trends highlight a comprehensive approach to managing diabetes and obesity, making GLP-1 therapies a focal point in chronic disease management in the United States.
Key Target Audience Healthcare Providers and Endocrinologists Diabetes Treatment Centers and Obesity Clinics Pharmaceutical Distributors and Retail Pharmacies Regulatory Authorities and Health Policy Makers Insurance Companies and Reimbursement Bodies Healthcare Research Institutions
FAQs about the United States GLP-1 Market
The GLP-1 market in the USA comprises drugs that activate GLP-1 receptors, primarily used to manage diabetes and obesity.
Rising diabetes and obesity rates, coupled with healthcare policies supporting these treatments, are primary drivers.
Both oral and injectable forms, including combination therapies, are available in the market.
GLP-1 drugs help with weight loss by reducing appetite and promoting satiety, thus aiding obesity management.
Yes, recent advancements include oral GLP-1 formulations and long-acting injectables for enhanced patient compliance.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis 2. Market Dashboard 3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Drug Type 3.2.2 By Application 3.2.3 By Distribution Channel 3.2.4 By Administration Route 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges 4. United States GLP-1 Market by Drug Type 4.1 Introduction 4.2 Market Size and Growth Rate by Drug Type (2024-2030) 4.2.1 Oral GLP-1 Agonists 4.2.1.1 Weekly Dosing Formulations 4.2.1.2 Daily Dosing Formulations 4.2.2 Injectable GLP-1 Agonists 4.2.2.1 Short-Acting GLP-1 Agonists 4.2.2.2 Long-Acting GLP-1 Agonists 4.2.3 Combination Therapies 4.2.3.1 GLP-1 and SGLT-2 Inhibitor Combo 4.2.3.2 GLP-1 and DPP-4 Inhibitor Combo 4.2.4 Others 4.2.4.1 GLP-1 and Insulin Combinations 5. United States GLP-1 Market by Application 5.1 Introduction 5.2 Market Size and Growth Rate by Application (2024-2030) 5.2.1 Diabetes Treatment 5.2.1.1 Type 2 Diabetes 5.2.1.2 Type 1 Diabetes (Off-label Use) 5.2.2 Obesity Treatment 5.2.2.1 BMI 30 and Above 5.2.2.2 BMI 27 with Comorbidities 5.2.3 Cardiovascular Health 5.2.3.1 High-risk Patients 5.2.3.2 Preventive Care 5.2.4 Others 5.2.4.1 Pre-diabetic Interventions 6. United States GLP-1 Market by Distribution Channel 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channel (2024-2030) 6.2.1 Hospitals and Clinics 6.2.1.1 Specialty Diabetes Centers 6.2.1.2 Obesity Clinics 6.2.2 Retail Pharmacies 6.2.2.1 Chain Pharmacies 6.2.2.2 Independent Pharmacies 6.2.3 Online Pharmacies 6.2.3.1 Direct-to-Patient Sales 6.2.3.2 Telemedicine Distributors 7. United States GLP-1 Market by Administration Route 7.1 Introduction 7.2 Market Size and Growth Rate by Administration Route (2024-2030) 7.2.1 Oral Tablets 7.2.1.1 Controlled Release Tablets 7.2.1.2 Immediate Release Tablets 7.2.2 Injectable Solutions 7.2.2.1 Subcutaneous Injections 7.2.2.2 Prefilled Syringes 7.2.3 Transdermal Patches 7.2.3.1 Extended Release Patches 8. Competitive Landscape 8.1 Company Profiles 8.1.1 Novo Nordisk (Denmark) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.2 Eli Lilly and Company (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.3 Pfizer (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.4 Sanofi (France) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.5 AstraZeneca (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.6 Boehringer Ingelheim (Germany) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.7 Johnson & Johnson (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.8 Merck & Co. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.9 Amgen (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.10 Viatris (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.11 Intarcia Therapeutics (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.12 GlaxoSmithKline (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.13 Roche (Switzerland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.14 Medtronic (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.15 Bristol Myers Squibb (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9. List of Tables and Figures List of Tables Table United States GLP-1 Market Size by Drug Type (2024-2030) Table Oral GLP-1 Agonists Market Size by Sub-type (2024-2030) Table Injectable GLP-1 Agonists Market Size by Sub-type (2024-2030) Table Combination Therapies Market Size by Sub-type (2024-2030) Table Others Market Size by Sub-type (2024-2030) Table United States GLP-1 Market Size by Application (2024-2030) Table Diabetes Treatment Market Size by Sub-type (2024-2030) Table Obesity Treatment Market Size by Sub-type (2024-2030) Table Cardiovascular Health Market Size by Sub-type (2024-2030) Table Others Market Size by Sub-type (2024-2030) Table United States GLP-1 Market Size by Distribution Channel (2024-2030) Table Hospitals and Clinics Market Size by Sub-type (2024-2030) Table Retail Pharmacies Market Size by Sub-type (2024-2030) Table Online Pharmacies Market Size by Sub-type (2024-2030) Table United States GLP-1 Market Size by Administration Route (2024-2030) Table Oral Tablets Market Size by Sub-type (2024-2030) Table Injectable Solutions Market Size by Sub-type (2024-2030) Table Transdermal Patches Market Size by Sub-type (2024-2030) List of Figures Figure United States GLP-1 Market Size and Growth Rate by Drug Type (2024-2030) Figure Oral GLP-1 Agonists Market Growth Rate by Sub-type (2024-2030) Figure Injectable GLP-1 Agonists Market Growth Rate by Sub-type (2024-2030) Figure Combination Therapies Market Growth Rate by Sub-type (2024-2030) Figure Others Market Growth Rate by Sub-type (2024-2030) Figure United States GLP-1 Market Size and Growth Rate by Application (2024-2030) Figure Diabetes Treatment Market Growth Rate by Sub-type (2024-2030) Figure Obesity Treatment Market Growth Rate by Sub-type (2024-2030) Figure Cardiovascular Health Market Growth Rate by Sub-type (2024-2030) Figure Others Market Growth Rate by Sub-type (2024-2030) Figure United States GLP-1 Market Size and Growth Rate by Distribution Channel (2024-2030) Figure Hospitals and Clinics Market Growth Rate by Sub-type (2024-2030) Figure Retail Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure Online Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure United States GLP-1 Market Size and Growth Rate by Administration Route (2024-2030) Figure Oral Tablets Market Growth Rate by Sub-type (2024-2030) Figure Injectable Solutions Market Growth Rate by Sub-type (2024-2030) Figure Transdermal Patches Market Growth Rate by Sub-type (2024-2030)
Tables Financial Overview of Key Companies
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United States market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United States GLP-1 Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue United Statesly. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United States GLP-1 Market for the past year and forecasts for the next six years. United States United States GLP-1 Market. Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United States GLP-1 Market Market categories. Market size and forecasts for each major application is provided in the context of United States market. The numbers provided in this report are derived on the basis of demand for United States GLP-1 Market from different application industries in different regions.
